Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | PPIA | P62937 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719077 | 0.91 | PTPN1 (0.43) | HTR2CHTR2BPPIAMAOBSLC6A4 | |
| SCHEMBL16231697 | 0.87 | MRGPRX4 (0.54) | PPIAMAOBNR4A2FFAR4MRGPRX4 | |
| SCHEMBL14718731 | 0.84 | HTR2C (0.43) | HTR2CMAOBSLC6A4 | |
| SCHEMBL14719523 | 0.83 | LMNA (0.45) | MAOBIDO1NR4A2 | |
| SCHEMBL14729714 | 0.82 | PTPN1 (0.50) | HTR2CHTR2BPPIAMAOBSLC6A4 | |
| SCHEMBL16231696 | 0.81 | MRGPRX4 (0.51) | HTR2CHTR2BMAOBNR4A2SLC6A4 | |
| SCHEMBL16231709 | 0.81 | MRGPRX4 (0.42) | HTR2CHTR2BPPIAMAOBNR4A2 | |
| SCHEMBL14719215 | 0.81 | KDM4E (0.47) | HTR2CPPIAMAOBSLC6A4 | |
| SCHEMBL28049960 | 0.81 | MAOB (0.44) | HTR2CMAOBSLC6A4MRGPRX4 | |
| SCHEMBL14718955 | 0.81 | L3MBTL1 (0.46) | HTR2CMAOBIDO1SLC6A4FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-28 | — | — | US | disclosed |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-28 | — | — | US | disclosed |
| US-20200121678-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-23 | — | — | US | disclosed |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | disclosed |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | disclosed |
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| EP-2748149-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | HTR2C 995/4885HTR2B 718/4885PPIA 4300/4885 |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | HTR2C 643/4885HTR2B 630/4885PPIA 1488/4885 |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | HTR2C 643/4885HTR2B 630/4885PPIA 1488/4885 |
| US-20200121678-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | HTR2C 643/4885HTR2B 630/4885PPIA 1488/4885 |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | HTR2C 643/4885HTR2B 630/4885PPIA 1488/4885 |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | HTR2C 643/4885HTR2B 630/4885PPIA 1488/4885 |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | HTR2C 643/4885HTR2B 630/4885PPIA 1488/4885 |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | HTR2C 643/4885HTR2B 630/4885PPIA 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.